Last edition
News about "CDSCO Approval"
Emcure Receives CDSCO Nod to Expand Poviztra's Use for MASH Indication
Emcure has received CDSCO approval to expand Poviztra's use for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), addressing a major unmet need in progressive liver disease treatment.
CDSCO Approval | 21/07/2026 | By News Bureau
Leiutis Pharma Announces CDSCO Approval for World's First Synthetic CBD Anxiety Therapy
Leiutis Pharmaceuticals has received CDSCO approval for the world's first synthetic CBD oral solution to treat mild to moderate anxiety disorders alongside cognitive behavioral therapy.
CDSCO Approval | 15/07/2026 | By News Bureau | 1804
CDSCO Approves AstraZeneca's Trastuzumab Deruxtecan Plus Pertuzumab Combination
AstraZeneca Pharma India has received CDSCO approval for trastuzumab deruxtecan plus pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.
CDSCO Approval | 12/06/2026 | By News Bureau | 101
Eli Lilly and Company Launches Lormalzi for Early-Stage Alzheimer's Treatment in India
Eli Lilly and Company India has launched Lormalzi, a once-monthly amyloid-targeting therapy approved for early-stage Alzheimer’s disease, marking a significant advancement in evidence-based treatment options for cognitive decline in India.
CDSCO Approval | 14/05/2026 | By News Bureau | 134
AstraZeneca Secures CDSCO Approval for Breast Cancer Drug in India
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell and distribute its breast cancer therapy Datopotamab Deruxtecan in India.
CDSCO Approval | 20/12/2025 | By Darshana | 199
Lilly India Receives CDSCO Approval for Donanemab to Treat Early Alzheimer's Disease
Eli Lilly and Company (India) Pvt. Ltd. has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) for donanemab, a treatment for adults in the early symptomatic stages of Alzheimer’s disease.
CDSCO Approval | 18/11/2025 | By Darshana | 564
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy